TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Echocardiographic volumetric response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to drop subject temperature 0.8-3.0°C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to induced mild hypothermia threshold (34ºC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in microbiologic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in symptomatic relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intubation difficulty scale (IDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: pCLE classification and scoring system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline Fugl-Meyer Assessment of Motor Recovery at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Functional Test for the Hemiplegic Upper Extremity at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement rate between recommendations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Return to work at 18 months after diagnosis
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of participants completing each procedure
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration (time) of each procedural session
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Serum mast cell tryptase values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived clinical impact
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of treatment related major complications
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with adverse events/serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients achieving hemostasis after 2 minutes of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Absence of air leak in lung at time of surgical closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tight closure achieved in dura mater at time of surgical closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cotinine Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Cognitive Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: average steps per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of time the patient is wearing the device properly
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Doses in the Initial Discharge Opioid Prescription
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of Patients for Whom the Number of Doses in the Discharge Opioid Prescription Equals the Number of Doses in the New Default Settings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of Participants Who Had at Least One Opioid Prescription Refill From University of Michigan During the Two Weeks After Surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of Patients Who Visited or Saw a University of Michigan Provider Due to Pain During the Two Weeks After Surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adverse event/Serious adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in onset of melatonin secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Marker of Fibrinolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tetanus antibody titers at day 28 post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diphtheria antibody titers at day 28 post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tetanus seroprotection rate at day 28 post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diphtheria seroprotection rate at day 28 post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: False-positive percentage
Endpoint domain: Adverse events/effects
Primary endpoint: lung inflammation measured by PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Catheterisation efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Leakage efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: MRI Diagnostic Yield of Cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Average Days to Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Clinician-Administered PTSD Scale (CAPS-IV)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stress (as Measured by Cortisol)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress (as Measured by Subjective Report)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Single Item Stress Measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 20-item Positive and Negative Affect Schedule
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lean and Fat Body Mass Composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of urinary uromodulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary exosomal UMODmRNA gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Perioperative risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of multiplex ELISA assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with Delayed Graft Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: NRS pain score around sternotomy incision site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual rate of acute COPD exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Composite event rate of all-cause death, stent thrombosis, myocardial infarction, and stroke
Endpoint domain: Mortality/survival
Primary endpoint: Reduction/improvement of cough symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: serum pepsinogen as a diagnostic marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change of Fruit intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Vegetable intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Physical activity practice
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Gastrointestinal graft-versus-host disease (GVHD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: intestinal protein synthesis stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of pain management strategies utilized
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sputum Neutrophil (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pulmonary Artery Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: high energy phosphate metabolites (Phosphocreatine (PCr))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability of BL-8040 in combination with Imatinib
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of galactose therapy in PGM1-CDG patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of galactose therapy in SLC35A2-CDG patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to N-acetylglucosamine (GlcNAc) therapy in NGLY1 deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in concentrations of interleukin-1β
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in concentrations of interleukin-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in concentrations of tumor necrosis factor α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fibrosis indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction of phase III of the migrating motor complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cognitive Function- Digit Span Total
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Psychopathology- PANSS Total
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall morbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on Posner Cueing Task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Subjects Achieving Either a 2g/dL Increase in Hb OR Normalization of Hb at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety following TAG vaccine administration
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Adherence to the Intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean HbA1c (glycosylated haemoglobin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Subjects With Human Serum Bactericidal Assay (hSBA) Seroresponse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects With Antidiphtheria and Antitetanus Toxin ≥1.0 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Concentrations (GMC) of Antipertussis Toxin (Anti-PT), Antifilamentous Hemagglutinin (Anti-FHA), and Antipertactin (Anti-PRN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: treatment prognosis for breast cancer patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ROI Peak/Ref Peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ROI TTP (Time to peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ROI AUC/Ref AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarkers related to lipid metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient red blood cells value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Need for autologous blood transfusion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Collagen synthesis in articular cartilage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Complete Response (CR) and Complete Response with incomplete blood count recovery (CRp)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of positive CMV results
Endpoint domain: Adverse events/effects
Primary endpoint: Acute rejection of transplanted kidney
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Angiographic occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in fat graft volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of spontaneous vaginal delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Daytime Partial Pressure of Carbon Dioxide in Arterial Blood (PaCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of opioid prescriptions complying with CDC recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Subjective Responses to Symptoms/Complaints
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Days alive and at home in the first 90 days after surgery
Endpoint domain: Mortality/survival
Primary endpoint: Incremental cost-effectiveness and cost-utility
Endpoint domain: Resource use
Primary endpoint: Time to Re-epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Diagnosis of eosinophilic esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Central Nervous System-Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time Till Relapse
Endpoint domain: Mortality/survival
Primary endpoint: 4 week changes in apoptosis biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional status: Barthel Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mini-Nutritional Assessment scores (MNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative delirium incidence rate [Confusion Assessment Method (CAM)]
Endpoint domain: Adverse events/effects
Primary endpoint: task-related cortical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Positive RDT Result
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of difference in SNP profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decision Self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Event Rate of All Hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Pathologic Antibody-Mediated Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with Left Ventricular Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Composite Safety Endpoint Based on MACCE
Endpoint domain: Adverse events/effects
Primary endpoint: Number of care gaps identified
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Knee joint biomechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual disease measured by PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent of Participants With Disease Flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced a Disease Flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Transfer to Intensive Care Unit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of Intubation
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of monoclonal B-cell lymphocytosis (MBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Adverse Events Related to Tocilizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Cough and Sputum PRO symptom domain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Adolescent Body Mass Index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functionality of signal measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: new hospital readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in ovarian reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Brain functional activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gastric emptying assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in urinary renin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in diuretic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accurate success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure successful
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Intra-Operative Hemostatic Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: CDP average
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximum inspiratory pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tc99m-MAA uptake within the tumor and surrounding structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients successfully established with pre-hospital ECPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound bioburden control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ): Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Change in Costs of UC-related Medical Care Excluding Adalimumab Costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Timed transfer into the Rex device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of sit to stand and stand to sit within the Rex device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of 1 Rex robotic assisted balance rehabilitation exercise session
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication Adherence Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Calprotectin concentration in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GTV volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in CM Diagnostic Pattern & Clinical Characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Body Constitution Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of valsartan and rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC last of valsartan and rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Battery voltage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pacing lead impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P wave amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: R wave amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pacing lead threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of CC-5013 in Myelofibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Hematological outcomes
Primary endpoint: Number of Participants With Pulmonary Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Radiostereometric analysis (RSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in nasal cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temperature Decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of additional Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: ureteric stent symptom questionnaire (USSQ) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Flap separation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Glandular excision time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Central lymph node dissection time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes